Document Detail


[Should we treat thalassemia-induced osteoporosis: two case reports].
MedLine Citation:
PMID:  23032499     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report two cases of beta-thalassemia-induced osteoporosis. A man and a woman presented an osteoporosis at the densitometry and were treated with bisphoshonate iv. All the studies analysed the efficacity of bisphosphonate, in particular zoledronate seems to be effective. Concerning the pathogenesis, the RANK-RANK-Ligand and OPG play a major role in bone-resorption and seem to be the principal implicated mechanism for the development of osteoporosis in BTM. At the moment there is no study evaluating the efficacity of denosumab in the BTM.
Authors:
M Lucini; D Stoll; B Aubry-Rozier; O Lamy
Publication Detail:
Type:  Case Reports; English Abstract; Journal Article    
Journal Detail:
Title:  Praxis     Volume:  101     ISSN:  1661-8157     ISO Abbreviation:  Praxis (Bern 1994)     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-03     Completed Date:  2012-12-04     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101468093     Medline TA:  Praxis (Bern 1994)     Country:  Switzerland    
Other Details:
Languages:  fre     Pagination:  1325-9     Citation Subset:  IM    
Affiliation:
Centre de Maladie Osseuse, Département de l'Appareil Locomoteur, CHUV, Lausanne.
Vernacular Title:
Faut-il traiter l'osteoporose liee a la thalassemie majeure: deux cas cliniques.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Adult
Antibodies, Monoclonal, Humanized / adverse effects,  therapeutic use
Bone Density Conservation Agents / adverse effects,  therapeutic use*
Diphosphonates / adverse effects,  therapeutic use*
Female
Humans
Hypogonadism / complications,  drug therapy
Imidazoles / adverse effects,  therapeutic use
Infusions, Intravenous
Male
Osteoporosis / diagnosis,  drug therapy*,  etiology*
beta-Thalassemia / complications*,  diagnosis,  drug therapy*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid; 4EQZ6YO2HI/denosumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Diabetic Neuropathies: Clinical sub-Types, Early Detection, and Asking Help from Neurologist].
Next Document:  Getting personal: understanding how genetic variation affects clinical outcomes in patients with tet...